Managing Anemia in CKD: Beyond Iron and ESAs
Iron therapy and erythropoiesis-stimulating agents are not always effective for anemia in patients with CKD. Nutritional interventions may be helpful in these cases.
Iron therapy and erythropoiesis-stimulating agents are not always effective for anemia in patients with CKD. Nutritional interventions may be helpful in these cases.
No difference seen in keratinocyte cancers or actinic keratoses for organ-transplant recipients receiving oral nicotinamide or placebo
Further, baseline vitamin D-related biomarkers lower for individuals with higher BMI
The 2017 KDIGO guideline for CKD-MBD may be too conservative, according to investigators.
A round up of studies suggests it is difficult to increase serum total 25-hydroxyvitamin D levels enough to effectively lower elevated parathyroid hormone (PTH) levels in overweight patients with chronic kidney disease.
But evidence suggests that reverse causation may play a role in the links between serum folate deficiency and dementia, all-cause mortality
The effect of cholecalciferol supplementation on parathyroid hormone levels and bone loss at the lumbar spine in kidney transplant recipients was studied in a placebo-controlled trial.
Previous studies indicate that selenium and selenoproteins are involved in erythropoiesis.
Risk appeared to be greater in trials testing >1 g/day dosing
Secondary analysis of randomized trial shows no difference in progression of KDIGO risk scores with daily vitamin D versus placebo